​​​​Introduction​

Our laboratory is a multidisciplinary laboratory of epigenetics, genomics, stem cell biology, immunology, chemical biology, bioinformatics and big data analysis. We committ to interpreting life phenomena through omics big data, using advanced epigenetic and bioinformatics technologies, combining computational (dry) and experimental (wet) methods to answer the important scientific questions of tumor immune responses, stem cell fate determination, and tissue/organ regeneration.

Our main interests are:

(1) Decode dysregulated RNA modifications in the tumor microenvironment, revealing how m⁶A in immune cells controls anti-tumor immunity. METTL14 in macrophages drives CD8⁺ T cell exhaustion via EBI3 (Cancer Cell, 2021), while YTHDF1 in dendritic cells impairs antigen presentation (Nature, 2019); targeting FTO with Dac51 enhances checkpoint blockade efficacy (Cell Metabolism, 2021).

(2) Discover nuclear m⁶A on chromatin-associated RNA(caRNA) directly regulates chromatin accessibility and transcription via YTHDC1–NEXT (Science, 2020), overturning the dogma that RNA modifications act only post-transcriptionally. This RNA epigenetics mechanism reshapes understanding of stem cell fate (Cell Proliferation, 2023; Life Medicine, 2023; SCIENCE CHINA Life Sciences, 2025).

(3) Develop multi-omics technologies and AI algorithm for precision oncology—mapping T cell translatomes to identify LARP4 as a therapeutic target (Nature Immunology, 2025), creating RNA modification profiling tools (Nature Methods, 2017; Molecular Cell, 2016), and building clinical machine learning diagnostics (Cell Research, 2018; Advanced Science, 2023).